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Analysis of survival following treatment of tumour-induced
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Sm_ry The outcome of 114 patients with tumour-induced hypercalcaemia (TIE) treated betwen January
1992 and June 1993 with intravenous pmidronate (APD) was retrspectively analysed. The median overall
survival was 55 days (range 3 days to >21 months): 86 days if systemic anti-cancer therapy was available and
only 35 days if not (P<0.0O0). Survival was also signifantly better for those who became normocalcaemic
post APD (53 days vs 19 days, P<0.001). There was no survival difference with respect to patiet sex, age,
tumour type, treatment ofbone metasases with radiotherapy, initial calium level, initial dose ofAPD or time
from tumour dianosis to first TIH. In those patients in whom systenmc anti-cancer therapy is available,
treatment with APD imprves survival, but in all other patients the primary aim of treatment should be
symptom control. This study confirms the dismal progo of TIH.
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Tumour-induced hypercacaemia (TIH) occurs in 8-10% of
patiets with malignant dises and is most common in
carcinoma of the lung, breast, kKiney and in haematological
malignancies (particularly myeloma) (Muggia, 1990). It is
usually associated with advanced disease and often, but not
always, with bone metastases (Mundy, 1990). The symptoms
associated with TIH inclue nausea, weakness, fatigue,
lethargy, constipation and confusion. Left untreated, TIH
may progress to coma and death (Ritch, 1990). Treatment of
T in the past has included forced diuresis, corticosteroids,
phosphates, mithramycin, calcitonin and gallium nitrate.
Each of these treatments has limitations and potential for
toxicity (Ritch, 1990).
The bisphosphonates are now well established as the treat-
ment of choice for TIH, and their role in controlling the
symptoms of TIH is also well documented (Ralston et al.,
1985). Their mode of action is not completely understood,
but the end result is an inhibition of bone resorption via
disruption ofthe normal osteoclast activity in bone (Coleman
and Purohit, 1993). Side-effects are rare and include transient
pyrexia, GI disturbance, asymptomatic hypocalaemia and
occasional lymphocytopenia.
The aim of this study was to assess the outcome in a series
ofpatients with TIH treated with intravenous aminohydroxy-
propylidene (pamidronate) (APD).
P nis an -ethad
A retrospective analysis was conducted of all patients who
were treated with APD at the time of their first episode of
TIH, at the Royal Marsden Hospital (London and Surrey),
between January 1992 and June 1993.
Pharmacy records were screened to identify all patients
who had received intravenous APD during this tme and
compuerised biochemistry results srned to find which of
these patients were hypercalcaeic. Those patients who had
previously been treated for TH (i.e. before January 1992)
with any standard anti-hypercakaemic therapy were ex-
cluded. Those patients who had receivd bisphosphonates in
the past for treatment of bone pain before becoming hyper-
cakcemic in the study period were included, as were those
patients who continued to receive APD for bone pain follow-
ing the episode of TIH under study.
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The serum calcium level before and after treatment with
APD was noted, as was any specific anti-cancer therapy after
treatment with APD. Al calcium levels were 'corrected'
according to the serm albumin (Varley et al., 1980):
Adjusted calcium (mmol1') = measured calcium
(mmol 1-') + 0.02 x [40- albumin (gl-)]
Normal laboratory values for this institution are calcium
2.1-2.6mmol 1, albumin 30-50 g 1-'. The pretreatment
rehydration regimens used varied, although standard hospital
policy recomm s that patients with hypercacaemia receive
at kast 21 of normal saline before treatment with APD.
Overall survival was calulated from first episode of TmH,
and analysed according to sex, age, tumour type, previous
treatment with bisphosphonates for bone pain, subsequent
anti-cancer treatment (chemotherapy and/or radiotherapy to
a site of bone metastases), time from tumour diagnosis,
normalisation of calcium level, initial serum calcium level
and initial dose of APD.
Survival curves were constructed using the Kaplan-Meier
product limit method. They were compared using the log-
rankr test Multivariate analysis was performed using Cox's
regression. The multivariate analysis gives an indication of
prognosis following TllH, taling into account factors which
are kInown at the time of the episode of TmH. The achieve-
ment of normocacaemia is time dependent, i.e. the longer
the patient survives and is followed up, the more likely he or
she is to achieve normocaemia. It is therefore not possible
to know soon after the episode ofTmH whether a patient will
become normocakaemic of not. Succe or failure in achiev-
ing normocacaemia was therefore not included in the mul-
tivariate analysis. Similarly, both the total dose of APD
received and the total number of courses of radiotherapy
given are time dependent and were therefore not included in
the survival analysis.
Redbt
One hundred and fourteen patients were identfied (44men
and 70 women) with a median age of 58 years (range 31-
83). Tumour types are listed in Table I, with breast, lung and
renal cell tumours being most common. The median time
from original diais ofmalignancy to the development of
TIH was 16 months (range 0-271 months). Five patients had
previously recived bisphosphonates for treatment of bone
pain before developing TIH.
The median serum calcium at time of first detection ofTable I Tumour type in patients presentig with TIH
Tumour type Number ofpatients
Breast 46
Lung 15
Renal 9
Myeloma 7
Gynaecologal 6
Head and neck 6
Gastrointestinal 5
Bladder 5
Sarcoma 4
Other 11
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TIH was 3.08 mmol 1-1 (2.65-4.66). The median serum cal-
cium at time of first treatment with APD was 3.18 mmol 1-'
(range 2.46-4.66). Serum calcium retuned to within normal
limits at some stage following treatment in 77 patients (68%).
The median dose of APD given as the initial treatment of
TIH was 60mg (range 15-90 mg). The median dose of APD
given from first episode of TIH to time of death or last
follow-up was 60 mg (I5-765 mg). Forty-one patients (36%)
were treated with APD on more than one occasion. Follow-
ing the first episode of hypercalaemia six patients received
further APD for bone pain.
Ninety-seven patients had died at time of analysis. The
median survival of all patients from time of first episode of
TIH to death or last follow-up was 55 days (range 3 days to
>21 months). Many patients had previously recived treat-
ment for their malignancy. Following the first episode of
TIH, specific systemic anti-cancer treatment was given to 42
patients. Twenty-four patients received chemotherapy, 12
hormonal therapy and six patients both chemotherapy and
hormone therapy. The median survival of patients who had
such therapy available was 86 days (range 16 days to > 15
months). The median survival ofpatients who did not receive
specific anti-cancer treatment following the first episode of
TIH was 35 days (range 3 days to >11 months) (P<0.001)
(Figure 1). Sixty-seven patients had one or more courses of
radiotherapy to one or more sites of bone metastases after
treatment with APD. The median survival of these patients
was 75 days, as compared with 42 days in those patients who
did not receive radiotherapy (P = 0.15). No patient in the
group analysed had been treated with strontium-89.
The median survival of the 77 patients who became nor-
mocakaenic following treatment with APD was 53 days as
compared with 19 days for those patients who did not
(P<0.001) (Figure 2).
There was no difference with respec to survival for sex,
age, tumour type, time since diags or kevl of serum
calcium at first diagnosis ofTIH or at time oftreatment with
APD (Table H). Previous treatment with phosphonates for
bone pain did not affect survival, but the number ofpatients
so treated was small. Those paients given >30 mg of APD
as the initial treatment of TIH fared no better than those
treated with <30mg.
Multivariate analysis of survival was undertaken examin-
ing the simultaneous effect of factors which were significant
or showed a suggestion of sign on univariate analysis.
These factors were systemic anti-cancer treatment, age and
radiotherapy. Systemic anti-cancer treatment and radio-
therapy were found to be of idependent prognostic value;
age was not significant. The hazard ratio for systemic treat-
ment was 0.36 (95% CI 0.23-0.57) and for radiotherapy 0.57
(0.38-0.88). Both factors were beneficial.
Although the bisphosphonates have in many ways revolu-
tionised the treatment of TIH owing to ease of adminita-
tion, efficacy and low toxicity, patients generally remain
normocakaemic for only 2-4 weeks (Ralston et al., 1989)
and TIH remains a preterminal event in most cases.
Time since hypercalcaemia (years)
Figwe 1 Survival by anti-cancer treatment. Sobd ine = treat-
ment (n=42); dashed lime=no treatment (n=72) (P<O.001).
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FugWe 2 Survival by achivement of norm emia after
APD. Solid line=yes (n = 77); dashed ine= no (n= 37)
(P<0.001).
In a hospital survey published in 1980, 58% of patients
with TIH treated with agents other than bisphosphonates
died within 3 months, and 79% were dead within a year
(Fisken et al., 1980). Warrell et al. (1988) compared cal-
citonin and gallium nitrate therapy for the treatment of TIH
and reported median survivals of 35 and 29 days respectively
in each arm. Ralston et al. reported an overall survival of 30
days in both a review of 126 patients treated with a range of
anti-hypercacaemic agents incuding APD (Ralston et al.,
1990) and in a dose-finding study of APD (Ralston et al.,
1988). O'Rourke et al. (1994) report a median survival of
only 2 months in 168 patients with TIH admitted to a
regional oncology centre in a 12 month period.
This study is consistent with the above series and confirms
the dismal prognosis of TIH. The overall survival of all
patients treated with APD was less than 2 months. Even for
those patients who could still receive specific anti-cancer
therapy (i.e. had not exhausted all oncological therapeutic
options) the median survival was less than 3 months. The
availability of anti-cancer therapy was a signiicant prognos-
tic factor however. Even though the median survival was
short, a small number of patients in this group survived for
many months (30% at 6 months, 20% at 1 year).
Those patients presenting with TllH who were considered
too unwell to receive APD were not taken into account in
this study. The true survival figures might therefore be even
worse than indicated. On the other hand, this may be
balned by those patients with only miklly elevated levels of
serm calcium who may have been asymptomatic and
therefore not given APD, e.g. before chemotherapy to which
they responded.
Failure to achieve normocalcaemia following treatment
with APD was the only other significnt poor prognostic
factor with respect to survival. Moreover, the difference
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Table H Factors related to survival in TIH (univariate analysis)
Hazard ratio
Variable No. Group (95% confidence interval) P-value
Sex 66 Femaak 1.00
48 Mak 1.28 (0.85-1.92) NS
Age (years) 63 <60 1.00
51 ,60 1.46 (0.97-2.21) NS
Tumour type 46 Breast 1.00
15 Lung 1.1 (0.58-2.09)
53 Other 0.99 (0.65-1.52) NS
Previous bisphosphonates 5 Yes 1.00
for bone pain 109 No 0.97 (0.39-2.42) NS
Anti-cancer treatment 72 No 1.00
following TIH 42 Yes 0.40 (0.27-0.60) P<0.001
Radiotherapy to site of 67 No 1.00
bone metastases 47 Yes 0.74 (0.49-1.10) NS
Time since tumour 58 < 18 1.00
diagnosis (months) 56 > 18 1.10 (0.74-1.64) NS
Normocalaemic following 77 Yes 1.00
APD 37 No 2.16 (1.28-3.62) P<0.001
Level of serum calcium 47 >2.6-3.0 1.00
(mmol I-') at first diagnosis 39 >3.0-3.5 1.17 (0.74-1.86)
of TlH 18 >3.5-4.0 1.22 (0.67-2.23) NS
10 >4.0 0.58 (0.28-1.18)
Level of serum calcium 37 >2.6-3.0 1.00
(mmol[') at tme of APD 47 >3.0-3.5 0.96 (0.61-1.53)
18 >3.5-4.0 0.72 (0.4-1.28) NS
6 >4.0 0.38 (0.16-0.86)
First APD dose (mg) 51 <i30 1.00
63 >30 1.01 (0.68-1.51) NS
between those who did and did not achieve normocalcaemia
may be confounded by the fact that some patients who
would have become normocalcaemic may have died before
doing so.
Age did not affect survival, supporting previous reports
which suggest that younger patients do not necessarily
tolerate treatment and disease better than older patients
(Harris, 1992). Similarly, sex and tumour type were not
significant. It was of interest in this study that neither time
from diagnosis to TIH (i.e. greater or less than 18 months
from original tumour diagnosis) nor the level of serum cal-
cium at time of treatment was relevant. There is still con-
troversy as to the correct dose of bisphosphonate necessary
to treat TIH. A dose of 30 mg of APD is considered subop-
timal by many but did not appear to affect survival adversely
in this study, although the success of palliation of symptoms
with this dose was not measured. Radiotherapy offers excel-
lent palliation for the pain associated with bone metastases
(Hoskin, 1988) but is not a systemic therapy and would
therefore not be expected to affect survival. The multivariate
analysis showed this to be beneficial however. This might
reflect the fact that only those patients surviving the initial
episode would live long enough to receive radiotherapy.
In summary, this study shows that for patients who have
not exhausted all oncological therapeutic possibilities (i.e. still
have a chance of responding to systemic anti-cancer therapy),
treatment with APD can prolong life as well as palliate the
symptoms of hypercalaemia. Although the median survival
was poor in this group, a few patients will survive for many
months, especially those with responsive tumours, e.g. breast
cancer.
The dismal prognosis of this condition, however, partic-
ularly in those patients in whom no further specific anti-
cancer treatment is possible, supports the contention that the
primary aim of treatment of TIH should be to achieve symp-
tom control rather than to improve survival. Although the
symptoms commonly associated with hypercalcaemia, i.e.
thirst, nausea, lethargy, malaise, drowsiness, constipation and
confusion, are often very distressing and should be treated,
the benefit of treating TIH in a patient in whom no further
anti-cancer therapy is possible and who presents with no
symptoms must be questioned in the light of these survival
data.
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